Colorectal Cancer
📧 Sign up to get email alerts when something new happens for Colorectal Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-03-21Clinical Trial Update: Study on the Prevention of Dermal Toxicity Caused by Regorafenib by Traditional Chinese Medicine TDX105 [Phase 2]
Phase 2 clinical trial evaluating TDX105 (traditional Chinese medicine) to prevent dermal toxicity caused by regorafenib in patients with ad…
-
CLINICAL_TRIALS trial_result · 2022-03-18Clinical Trial Update: Trifluridine/Tipiracil (TAS-102) With or Without Thalidomide for the Treatment of Metastatic Colorectal Cancer [Phase 2]
Phase 2 trial evaluating trifluridine/tipiracil (TAS-102) with or without thalidomide for metastatic colorectal cancer.
-
CLINICAL_TRIALS trial_result · 2022-03-16Clinical Trial Update: Study of Pembrolizumab (MK-3475) vs Standard Therapy in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (MK-3475-177/KEYNOTE-177) [Phase 3]
This Phase 3 trial (MK-3475-177/KEYNOTE-177) compares pembrolizumab to standard therapy in MSI-H/dMMR stage IV colorectal cancer. Results we…
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer. [Phase 3]
Phase 3 trial comparing rivaroxaban to placebo for extended antithrombotic prophylaxis after laparoscopic colorectal cancer surgery; study c…
-
CLINICAL_TRIALS trial_result · 2022-03-11Clinical Trial Update: A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer [Phase 2]
Phase 2 trial comparing mXELIRI plus bevacizumab to FOLFIRI plus bevacizumab as first-line therapy for metastatic colorectal cancer has comp…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-03-09Clinical Trial Update: Lidocaine for Oxaliplatin-induced Neuropathy [Phase 1, Phase 2]
Phase 1/2 trial evaluating lidocaine for oxaliplatin-induced neuropathy has completed with results posted in 2022.
-
FDA approval · 2022-03-08FDA Approved: OXALIPLATIN — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for oxaliplatin by Mylan Institutional LLC, finalizing changes to the generic product's labeling und…
-
CLINICAL_TRIALS trial_result · 2022-03-08Clinical Trial Update: Anlotinib Plus Penpulimab (AK105) for Chemo-refractory Metastatic Colorectal Cancer:ALTER-C003 [Phase 2]
Phase 2 trial update evaluating anlotinib plus penpulimab (AK105) for chemo-refractory metastatic colorectal cancer (ALTER-C003).
-
CLINICAL_TRIALS trial_result · 2022-03-03Clinical Trial Update: A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy [Phase 1, Phase 2]
Clinical trial updates on GC1118 combined with chemotherapy are completed in Phase 1/2 for metastatic colorectal cancer and solid tumors.
-
CLINICAL_TRIALS trial_result · 2022-03-02Clinical Trial Update: A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI [Phase 1, Phase 2]
Phase 1/2 trial investigating SCO-101 in combination with FOLFIRI for metastatic colorectal cancer with acquired resistance to FOLFIRI.
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: An Investigational Immunotherapy Study of Nivolumab With Standard of Care Therapy vs Standard of Care Therapy for First-Line Treatment of Colorectal Cancer That Has Spread [Phase 2, Phase 3]
A clinical trial evaluating nivolumab plus standard of care versus standard of care in first-line colorectal cancer has completed (Phase 2/3…
-
CLINICAL_TRIALS trial_result · 2022-02-25Clinical Trial Update: IMPROVE Intervention Trial Implementing Non-invasive Circulating Tumor DNA Analysis to Optimize the Operative and Postoperative Treatment for Patients With Colorectal Cancer [Phase 2]
Phase 2 trial updating the IMPROVE intervention using non-invasive circulating tumor DNA to guide operative and postoperative treatment in c…
-
FDA approval · 2022-02-11FDA Approved: BRAFTOVI — Supplemental Application (Array BioPharma Inc.)
The FDA approved a supplemental application for BRAFTOVI (encorafenib) submitted by Array BioPharma Inc. The specific nature of the suppleme…
-
CLINICAL_TRIALS trial_result · 2022-02-07Clinical Trial Update: Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC [Phase 2]
Phase 2 trial evaluating regorafenib with 5-fluorouracil/leucovorin beyond progression in metastatic colorectal cancer has been terminated; …
-
CLINICAL_TRIALS trial_result · 2022-01-26Clinical Trial Update: Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy in Adjuvant Colorectal Cancer [Phase 3]
Phase 3 trial update for preventive treatment of oxaliplatin-induced peripheral neuropathy in adjuvant colorectal cancer; the study is termi…
-
CLINICAL_TRIALS trial_result · 2022-01-21Clinical Trial Update: A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy [Phase 2]
Phase II single-arm exploratory study of pemigatinib in advanced gastric and colorectal cancer patients with FGFR alterations after standard…
-
CLINICAL_TRIALS trial_result · 2022-01-20Clinical Trial Update: mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer [Phase 2]
Phase 2 trial comparing mFOLFOXIRI with mFOLFOX6 or CapeOx as adjuvant chemotherapy for stage IIIB/IIIC colorectal cancer.
-
FDA approval · 2022-01-14FDA Approved: CAPECITABINE — Supplemental Application (Dr. Reddy's Laboratories Limited)
FDA approved a supplemental application for Capecitabine from Dr. Reddy's Laboratories Limited.
-
CLINICAL_TRIALS trial_result · 2022-01-14Clinical Trial Update: Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer [Phase 2]
Phase 2 trial evaluating camrelizumab in combination with trastuzumab and chemotherapy in HER2-positive advanced colorectal cancer.
-
FDA approval · 2022-01-13FDA Approved: OXALIPLATIN — Supplemental Application (Eugia US LLC)
FDA approved the supplemental application for Oxaliplatin from Eugia US LLC, granting regulatory approval of a generic oxaliplatin product.
-
CLINICAL_TRIALS trial_result · 2022-01-11Clinical Trial Update: Efficacy of Chemotherapy, Associated to Either Cetuximab or Bevacizumab, in KRAS Wild-type Metastatic Colorectal Cancer Patients With Progressive Disease After Receiving First-line Treatment With Bevacizumab [Phase 2]
Phase 2 trial assessing chemotherapy plus either cetuximab or bevacizumab in KRAS wild-type metastatic colorectal cancer after progression o…
-
CLINICAL_TRIALS research · 2022-01-11Clinical Trial Update: EL CENTRO: Engaging Latinos in the Center of Cancer Treatment Options [NA]
Clinical trial update for EL CENTRO, focusing on engaging Latinos in cancer treatment decisions; trial status completed with posted results …
-
CLINICAL_TRIALS trial_result · 2021-12-28Clinical Trial Update: Increasing Uptake of Evidence-Based Screening Services Through CHW-led Multi-modality Intervention [NA]
A completed clinical trial investigating a CHW-led multi-modality intervention to increase uptake of evidence-based screening services, with…
-
CLINICAL_TRIALS trial_result · 2021-12-20Clinical Trial Update: Radiotherapy Combined With Tislelizumab and Irinotecan in MSS/pMMR Recurrence and Metastatic Colorectal Cancer [Phase 2]
Phase 2 trial evaluating the combination of radiotherapy, tislelizumab, and irinotecan for mismatch repair-proficient, microsatellite stable…
-
CLINICAL_TRIALS trial_result · 2021-12-17Clinical Trial Update: Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M) [Phase 3]
Phase 3 trial POLAR-M investigating preventive treatment for oxaliplatin-induced peripheral neuropathy in metastatic colorectal cancer was t…